This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D. Establishing the prevalence and prevalence at birth of hemophilia in males. Ann Intern Med 2019; 171(8): 540–6. doi: 10.7326/m19-1208%m31499529.IorioAStonebrakerJSChambostHMakrisMCoffinDEstablishing the prevalence and prevalence at birth of hemophilia in males20191718540610.7326/m19-1208%m31499529Open DOISearch in Google Scholar
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26(S6): 1–158. doi: 10.1111/hae.14046.SrivastavaASantagostinoEDougallAWFH Guidelines for the Management of Hemophilia, 3rd edition202026S6115810.1111/hae.1404632744769Open DOISearch in Google Scholar
Munn J, Khair K, Scott A, et al. Patient and caregiver perceptions of a pre-filled diluent syringe (MixPro®). J Haem Pract 2016; 3(1): 33–8. doi: 10.17225/jhp00073MunnJKhairKScottAPatient and caregiver perceptions of a pre-filled diluent syringe (MixPro®)20163133810.17225/jhp00073Open DOISearch in Google Scholar
Poonnoose P, Carneiro JDA, Cruickshank AL, et al. Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage – the MUSFIH study. Haemophilia 2017; 23(4): doi: 538–46. 10.1111/hae.13242.PoonnoosePCarneiroJDACruickshankALEpisodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage – the MUSFIH study20172345384610.1111/hae.1324228574179Open DOISearch in Google Scholar
van den Berg HM. From treatment to prevention of bleeds: what more evidence do we need? Haemophilia 2017; 23(4): 494–6. doi: 10.1111/hae.13256.van den BergHMFrom treatment to prevention of bleeds: what more evidence do we need?2017234494610.1111/hae.1325628544023Open DOISearch in Google Scholar
Centers for Disease Control and Prevention. Community Counts Registry Report – Males with Hemophilia 2014–2017. 16. Treatment / Treatment Regimen and Hemophilia Severity; 2020. Available from: https://www.cdc.gov/ncbddd/hemophilia/communitycounts/registry-report-males/treatment.html (accessed 28 July 2022).Centers for Disease Control and PreventionTreatment / Treatment Regimen and Hemophilia Severity;2020Available from: https://www.cdc.gov/ncbddd/hemophilia/communitycounts/registry-report-males/treatment.html (accessed 28 July 2022).Search in Google Scholar
Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10(2): 165–8. doi: 10.2450/2012.0147-11.MakrisMProphylaxis in haemophilia should be life-long2012102165810.2450/2012.0147-11332077422337280Open DOISearch in Google Scholar
Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med 2013; 4: 49–56. doi: 10.2147/jbm.S43734.SaxenaKBarriers and perceived limitations to early treatment of hemophilia20134495610.2147/jbm.S43734Open DOISearch in Google Scholar
Franchini M. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus 2010; 8(4): 292–6. doi: 10.2450/2010.0067-10.FranchiniMPlasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better201084292610.2450/2010.0067-10295749620967172Open DOISearch in Google Scholar
Mannucci PM. Hemophilia and related bleeding disorders: a story of dismay and success. Hematology Am Soc Hematol Educ Program 2002; 1–9. doi: 10.1182/asheducation-2002.1.1.MannucciPMHemophilia and related bleeding disorders: a story of dismay and success20021910.1182/asheducation-2002.1.112446416Open DOISearch in Google Scholar
United States Government. Federal Register. Determination of regulatory review period for purposes of patent extension: antihemophilic factor concentrate (recombinant). Washington DC, USA; 1993.United States GovernmentWashington DC, USA1993Search in Google Scholar
Pfizer; Wyeth Pharmaceuticals LLC. BeneFIX®: Highlights of prescribing information. Revised 4/2021. Available from: https://www.fda.gov/media/73556/download (accessed 28 July 2022).PfizerBeneFIX®: Highlights of prescribing information. Revised 4/2021. Available from: https://www.fda.gov/media/73556/download (accessed 28 July 2022).Search in Google Scholar
Musso R, Santoro R, Coppola A, et al. Patient preference for needleless factor VIII reconstitution device: the Italian experience. Int J Gen Med 2010; 3: 203–8. doi: 10.2147/ijgm.s12096.MussoRSantoroRCoppolaAPatient preference for needleless factor VIII reconstitution device: the Italian experience20103203810.2147/ijgm.s12096291553220689694Open DOISearch in Google Scholar
Cimino E, Linari S, Malerba M, et al. Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries. Patient Prefer Adherence 2014; 8: 1713–20. doi: 10.2147/PPA.S64709.CiminoELinariSMalerbaMPatient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries2014817132010.2147/PPA.S64709427029925525348Open DOISearch in Google Scholar
Ingle RG, Fang W-J. Prefilled dual chamber devices (DCDs) – Promising high-quality and convenient drug delivery system. Int J Pharm 2021; 597: 120314. doi: 10.1016/j.ijpharm.2021.120314.IngleRGFangW-JPrefilled dual chamber devices (DCDs) – Promising high-quality and convenient drug delivery system202159712031410.1016/j.ijpharm.2021.12031433540011Open DOISearch in Google Scholar
Pollard D, Khair K, Percier C, Wong Y, Shoemark R. Evaluation of a pre-filled diluent syringe (MixPro) among patient/carer users and nurses. J Haem Pract 2018; 5(1): 12–23. doi: 10.17225/jhp00106.PollardDKhairKPercierCWongYShoemarkREvaluation of a pre-filled diluent syringe (MixPro) among patient/carer users and nurses201851122310.17225/jhp00106Open DOISearch in Google Scholar
Novo Nordisk. NovoSeven RT coagulation factor VIIa (recombinant). 2019. Available from: https://www.novosevenrtpro.com/resources/patient-support/patient-education/mixpro-brochure.html (accessed 28 July 2022).Novo Nordisk2019Available from: https://www.novosevenrtpro.com/resources/patient-support/patient-education/mixpro-brochure.html (accessed 28 July 2022).Search in Google Scholar
West Pharmaceutical Services. Mix2Vial. 2017. Available from: https://www.westpharma.com/-/media/WestPharma/Files/Products/Mix2Vial-Information-Sheet.pdf (accessed 28 July 2022).West Pharmaceutical Services2017Available from: https://www.westpharma.com/-/media/WestPharma/Files/Products/Mix2Vial-Information-Sheet.pdf (accessed 28 July 2022).Search in Google Scholar
Octapharma USA Inc. WILATE: Highlights of prescribing information. Revised September 2019. Available from https://www.fda.gov/media/77812/download (accessed 28 July 2022).Octapharma USA IncRevised September 2019. Available from https://www.fda.gov/media/77812/download (accessed 28 July 2022).Search in Google Scholar
Grifols Biologicals LLC. Alphanate: Highlights of prescribing information. Revised 06/2018. Available from: https://www.grifols.com/documents/260038/65508/ft-alphanate-us-en/a9f2f9c9-05eb-4fac-a7d3-5f091c198cff (accessed 28 July 2022).Grifols Biologicals LLCRevised 06/2018. Available from: https://www.grifols.com/documents/260038/65508/ft-alphanate-us-en/a9f2f9c9-05eb-4fac-a7d3-5f091c198cff (accessed 28 July 2022).Search in Google Scholar
Grifols Biologicals LLC. Coagulation factor IX (human); AlphaNine® SD. Revised July 2013. Available from: https://www.grifols.com/documents/260038/89417/ft_alphanine_malasia_EN/a1bc830a-346a-474f-8bcc-4faca132c559 (accessed 29 July 2022).Grifols Biologicals LLCAlphaNine® SD. Revised July 2013. Available from: https://www.grifols.com/documents/260038/89417/ft_alphanine_malasia_EN/a1bc830a-346a-474f-8bcc-4faca132c559 (accessed 29 July 2022).Search in Google Scholar
CSL Behring. Idelvion: Summary of product characteristics. 2016; last updated 15/12/2021. 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf (accessed 28 July 2022).CSL Behring2016last updated 15/12/2021. 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf (accessed 28 July 2022).Search in Google Scholar
CSL Behring. Hexilate: Highlights of prescribing information. Revised 5/2016. Available from: https://labeling.cslbehring.com/PI/US/HelixateFS/EN/HelixateFS-Prescribing-Information.pdf (accessed 28 July 2022).CSL BehringRevised 5/2016. Available from: https://labeling.cslbehring.com/PI/US/HelixateFS/EN/HelixateFS-Prescribing-Information.pdf (accessed 28 July 2022).Search in Google Scholar
Novo Nordisk. Novoeight: antihemophilic factor (recombinant): Highlights of prescribing information. 07/2020. Available from: https://www.novo-pi.com/novoeight.pdf (accessed 28 July 2022).Novo Nordisk07/2020. Available from: https://www.novo-pi.com/novoeight.pdf (accessed 28 July 2022).Search in Google Scholar
Novo Nordisk. Refixia: Summary of product characteristics. 2017; last updated 07/03/2022. Available from: https://www.ema.europa.eu/en/documents/product-information/refixiaepar-product-information_en.pdf (accessed 28 July 2022).Novo Nordisk2017last updated 07/03/2022. Available from: https://www.ema.europa.eu/en/documents/product-information/refixiaepar-product-information_en.pdf (accessed 28 July 2022).Search in Google Scholar
Genentech, Inc. HEMLIBRA® (emicizumab): Highlights of prescribing information. Revised: 11/2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf (accessed 28 July 2022).Genentech, IncRevised: 11/2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf (accessed 28 July 2022).Search in Google Scholar
Bradley-Terry model. Encyclopedia of Mathematics. Revision 24 March 2012. Available from: https://encyclopediaofmath.org/index.php?title=Bradley-Terry_model&oldid=22181 (accessed 28 July 2022).Revision 24 March 2012. Available from: https://encyclopediaofmath.org/index.php?title=Bradley-Terry_model&oldid=22181 (accessed 28 July 2022).Search in Google Scholar
Bradley-Terry model. Encyclopedia of Mathematics. Revision 30 May 2020. Available from: https://encyclopediaofmath.org/index.php?title=Bradley-Terry_model&oldid=46143 (accessed 28 July 2022).Revision 30 May 2020. Available from: https://encyclopediaofmath.org/index.php?title=Bradley-Terry_model&oldid=46143 (accessed 28 July 2022).Search in Google Scholar
Novo Nordisk. Rebinyn: Highlights of prescribing information. Revised 06/2017. Available from: https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Package-Insert---REBINYN.pdf (accessed 28 July 2022).Novo NordiskRevised 06/2017. Available from: https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Package-Insert---REBINYN.pdf (accessed 28 July 2022).Search in Google Scholar